<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Protalix Biotherapeutics</title>
	<atom:link href="http://www.stockbloghub.com/tag/protalix-biotherapeutics/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PLX) Protalix BioTherapeutics Wins Orphan Drug Status</title>
		<link>http://www.stockbloghub.com/2009/09/09/plx-protalix-biotherapeutics-wins-orphan-drug-status/14788</link>
		<comments>http://www.stockbloghub.com/2009/09/09/plx-protalix-biotherapeutics-wins-orphan-drug-status/14788#comments</comments>
		<pubDate>Thu, 10 Sep 2009 02:47:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix Biotherapeutics]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14788</guid>
		<description><![CDATA[Yesterday, Protalix BioTherapeutics, Inc. (PLX) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to prGCD for the treatment of Gaucher disease, an enzyme disorder that can cause liver and neurological problems. The drug is currently being evaluated in a phase III trial which is scheduled to end this month. Top-line results are expected in October 2009. The company intends to file a New Drug Application (NDA) with the FDA before the end of the year. Drugs that treat diseases affecting 200,000 or fewer U.S. patients per year are granted &#8220;orphan drug&#8221; status by the FDA. Drugs in this umbrella qualify for priority and potentially faster review times. They also enjoy funding and tax savings to support its clinical development. Last month, the U.S. agency ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/plx-protalix-biotherapeutics-wins-orphan-drug-status/14788/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

